



PCT/GB 2003 / 0 0 1 0 4 9



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 23 APR 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

P. Mahoney

Dated

8 April 2003

BEST AVAILABLE COPY

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference P33676GB/PWC

2. Patent application number

(The Patent Office will fill in this part)

0205910.3

13 MAR 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Sense Proteomic Limited
Babraham Hall
Babraham
Cambridge CB2 4AT
United Kingdom
823848 7001
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Arrays and Methods

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Kilburn & Strode
20 Red Lion Street
London
WC1R 4PJ

Patents ADP number (if you know it)

125001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0
Description 30
Claim(s) 3
Abstract 0
Drawing(s) 4+4 EN

10. If you are also filing any of the following, state how many against each item.

Priority documents 0
Translations of priority documents 0
Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0
Request for preliminary examination and search (Patents Form 9/77) 0
Request for substantive examination (Patents Form 10/77) 0
Any other documents (please specify) 0

11.

I/We request the grant of a patent on the basis of this application.

Signature Kilham & Strode Date 13/03/02

12. Name and daytime telephone number of person to contact in the United Kingdom

Paul Chapman
Tel: 020 7539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
b) Write your answers in capital letters using black ink or you may type them.
c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
e) Once you have filled in the form you must remember to sign and date it.
f) For details of the fee and ways to pay please contact the Patent Office.

Arrays and Methods

5 A multitude of cellular signalling and homeostatic processes are mediated by transmembrane proteins such as ion channels, receptors and transporters. All of these protein classes interconnect with signalling, regulatory, scaffolding and adapter proteins through protein-protein interactions involving cytoplasmic domains.

10 Ion channels, membrane bound receptors such as G-protein-coupled receptors and many cell surface transporters are comprised of protein subunit complexes, consisting of homomeric or heteromeric assemblies of subunits (termed herein as accessory proteins) on the cytoplasmic face of the membrane. The ability of these protein groups to form complexes in a combinatorial manner provides a mechanism for tissue specific expression of transmembrane protein complexes with the requisite biophysical properties or modulator sensitivity. Increasingly, the determinants of subunit interactions are being located to defined domains within these subunit structures. Understanding the interactions of these domains will aid elucidation of membrane protein assembly in native systems and will identify modulatory proteins important for protein function within a cell. Further, perceived wisdom within these research fields recognises that perturbing the interaction between the accessory cytoplasmic subunits and the membrane bound portion of a transmembrane protein, once it is identified, could represent a highly tissue selective and therefore specific way of regulating the activity of the membrane bound molecule. Exogenous inhibitors of accessory protein interactions and hence subunit or modulatory protein assembly, may therefore provide novel, tissue-specific therapeutic targets.

25 Voltage gated potassium (K_v) channels and calcium (Ca^{2+}) channels are recognised as important therapeutic targets in many disorders including those of the CNS, heart, lungs and bladder. Both channel types have a principal pore-forming, voltage-sensing α -subunit. K_v channels require assembly of four

30

similar α -subunits, each containing six transmembrane segments, whereas calcium channels have a single α -subunit with 24 transmembrane segments, packaged into four 'pseudosubunits' of six transmembrane segments [1]. Both Kv and Ca^{2+} channels co-assemble with structurally similar cytoplasmic β -subunits via well-defined domains within the α -subunit. These can affect channel gating to various extents and can dramatically alter surface expression efficiency of α -subunits through mechanisms that may resemble or mimic the interaction of membrane proteins with authentic molecular chaperones [2]. To date, there have been six β -subunits identified for each of the two channel types. The ability of the Ca^{2+} channel β -subunits to assemble with the six α -subunits has been determined [3] but the interactions of the Kv channel β -subunits with the twenty or so α -subunits is less well established and it is not yet known in detail which combinations of β - and α -subunits are truly biologically relevant since the methods of analysis currently available are relatively crude (see below).

Receptors, in particular G-protein coupled receptors, are recognised as an extremely important group of cell surface proteins and they perform a wide variety of functions in many systems [4]. These 7-12 transmembrane proteins are grouped into three families, A, B and C, within which are many subtypes. Each GPCR interacts with at least one G-protein at its cytoplasmic face although the nature and identity of these interactions is poorly understood and is currently impossible to predict from bioinformatics. G-proteins, as well as complexing with GPCR's also interact with K^{+} and Ca^{2+} channel subunits in a specific manner with striking results [5].

Proteins at the cell surface that allow entry of bulky molecules represent a third class of membrane proteins, transporters, that complex with multiple cytosolic protein subunits in order to function but here again the exact nature and identity of these interactions is poorly characterised at present due to limitations in current analysis methodologies.

New methodologies which enable the highly parallel *in vitro* characterisation, including determination of equilibrium and kinetic binding parameters, of protein subunit binding interactions between various putative subunit partners will be tremendously useful in this field, particularly if they also allow assessment of the ability of potentially therapeutic compounds to modulate such interactions. Current methods for studying these interactions rely on cumbersome cell-based techniques such as electrophysiological analysis, or low throughput *in vitro* binding systems such as pull-down/immunoprecipitation assays. By contrast, the present invention describes an array-based method whereby the *in vitro* binding of soluble, functional domains of membrane-bound proteins, such as ion channels, cell surface receptors and transporters to arrays of immobilised cytoplasmic accessory proteins can be characterised in detail. The invention allows binding affinity and specificity of the protein-protein interaction to be determined and also allows the actions of inhibitors/competitors of the interaction to be explored in a highly parallel system.

The yeast two-hybrid system has been used to detect interactions between, for example, ion channel protein domains. This approach has been reasonably successful in identifying binding domains and in determining the effect of amino acid substitutions on the interaction. However, this method cannot provide quantitative information about binding affinities and cannot address the potential of exogenous substances to modulate the interactions. Alternatively, cell-based systems, for example whole-cell electrophysiology following subunit expression in *Xenopus* oocytes or mammalian cell lines, have been used to study ion channel assembly. This approach is technically difficult, inherently time-consuming and provides limited information about the actual binding events due to the measurement of downstream effects, ie whole-cell currents.

Biochemical methods have been used to isolate individual components of ion channel assemblies in native and recombinant systems. Co-immunoprecipitation experiments and affinity purification of channel subunits have been used to identify components of ion channel complexes. However, neither method provides detailed information about binding affinities or is suitable for screening potential modulators of subunit interactions. In the case of Ca^{2+} channels, fragments of one particular α -subunit have been immobilised on agarose beads as fusions to GST and the binding of *in vitro* translated β -subunits was used to more closely define the specific region of the α -subunit involved in the interaction [6]. Detailed information on binding affinities were not available in this study and it is not clear that the alpha subunit was correctly folded in this study.

Protein overlay binding examines binding interactions directly between a soluble peptide/protein and a target protein immobilised on a membrane support [7]. During this procedure proteins are initially dissociated and separated by SDS-PAGE and transferred to a nitrocellulose filter as for Western blotting. The denaturing step implicit in this method however suggests that the proteins assayed in this technique cannot be functional (i.e. folded) and therefore biologically active. Attempts can be made to renature the protein before binding of a soluble, labelled protein is investigated however the success rate here is poor..

Identification of native interactions between membrane proteins and accessory proteins, and the binding domains involved, have been investigated using various cell-based methods. For example, the native combinations of α and β Kv channel subtypes within a complex have been probed using co-purification with antibodies or subtype-specific toxins [9,10]. Yeast two-hybrid experiments have been widely used to identify protein-protein interaction domains and, for example, were used to identify the region of the N-terminal T1 domain of Kv channels that interacts with the cytoplasmic β

subunits [11]. The ability of proteins to interact in a model cell has been investigated using recombinant expression techniques. Examples include co-expression of voltage-gated ion channels and functional characterisation using electrophysiology [3,11,12], and the expression of chimeric and mutant GPCRs [reviewed in 13,14]. The perceived wisdom derived from such experiments is that the α and β subunits form a stable complex in the ER which does not subsequently dissociate.

Binding interactions between domains of membrane proteins and the domains of other subunits or their cytoplasmic partners, following separate expression, have been studied using pull-down assays on a one-by-one basis. The tetramerisation domains of K^+ channel transmembrane subunits have been examined in this way [15]. Intracellular domains of Ca^{2+} channels binding to β subunits [6] or SNARE proteins [16], the 5-HT_{2A} GPCR binding to arrestins [17] and the CFTR transporter binding to the adapter protein AP-2 [18] have been examined by immobilising the membrane protein domain on beads. Alternatively, the cytoplasmic Homer protein has been immobilised on beads to show the interaction with metabotropic glutamate receptors expressed in a cell lysate [19]. Cross-linking experiments have been performed between CFTR and AP-2 in microtiter plates [18], but in this case proteins were not immobilised. Protein-overlay experiments allow a number of binding interactions to be identified simultaneously. This technique was used to show binding of labelled *Drosophila* INAD to immobilised TRP Ca^{2+} channels [20]. This technique allows a number of proteins to be fractionated in different lanes of an SDS-PAGE gel and then immobilised on a nitrocellulose filter to be probed for binding.

The nature of the techniques described above means that the protein analysis usually either involves co-expression of the potential interacting partner, or involves denaturation of one or more of the potential partners, prior to the binding assay. Invariably they are low throughput and do not yield

detailed information on binding specificity or affinity and are not generally compatible with small molecule inhibitor studies. To overcome such problems, the Inventors have devised an array of separate, and importantly, functional, accessory proteins that were not originally co-expressed with the membrane protein components. Such an array allows, for the first time, the quantitative determination of interactions in a highly parallel manner.

Thus in a first aspect the invention provides an array of cytosolic accessory proteins which in their natural state are normally bound to membrane proteins, for example in a regulatory capacity. Such membrane proteins can be members of a family of homologous membrane proteins for example, ion-channels, G protein coupled receptors or transmembrane transporter proteins.

The accessory proteins on the array can be members of a family of homologous accessory proteins, for example ion-channel subunits (for example, β -subunits), receptor interacting proteins (for example, G proteins, arrestins and G protein receptor kinases) or accessory proteins for transporters (for example transporter protein interacting proteins). Particularly envisaged are arrays wherein the accessory proteins are K^+ -channel β -subunits, Ca^{2+} -channel β -subunits, G protein subtypes, for example, $G\alpha$, $G\beta/\gamma$ or accessory proteins for transporters. Examples include Kv β -subunits channel e.g. $\beta 1.1$, 1.2 , 1.3 , 2.1 , 2.2 , 3.1 , 3.2 , 4 , Calcium channel β -subunits e.g. $\beta 1a$, $\beta 1b$, $\beta 1c$, $\beta 2a$, $\beta 2b$, $\beta 2c$, $\beta 3a$, $\beta 3b$, $\beta 4$, G protein families e.g. G_s family (α_s and α_{olf}), G_t family, G_i family (α_o , α_{i1} - α_{i13} , α_z), G_{i-0} family, G_{q-11} family (α_q , α_{11} , α_{14} , α_{15} , α_{16} , α_{12} , α_{13}) and $G_{\alpha\text{-sensory}}$ family ($\alpha_{t\text{-rod}}$, α_{gust}) and $\beta\gamma$ family (γ_t , γ_1 , γ_2 , γ_3 etc.), or accessory proteins to transporter proteins (for example serotonin and glycine transporter proteins).

In a second aspect, the invention provides a method for determining the interacting accessory proteins for a given membrane protein, said method comprising the steps of:

- 5 (i) providing an array of candidate accessory proteins from one or more protein families of interest,
- (ii) contacting the array with cytosolic fragments of said membrane protein and/or cytosolic fragments of other related membrane protein family members,
- (iii) detecting/identifying the interacting partners.

10 In a third aspect the invention provides a method for screening compounds or peptides or proteins for the ability to interact selectively with an accessory protein, said method comprising the steps of:

- (i) providing an array of accessory proteins from one or more protein families of interest,
- 15 (ii) contacting the array with compounds or peptides or proteins,
- (iii) identifying the interacting partners.

This method optionally comprises the additional step (iv) of quantitating the interaction of the interacting partners.

20 Also provided is a method for screening compounds or peptides or proteins for the ability to selectively modulate the interaction between an accessory protein and a membrane protein, said method comprising the steps of

- (i) providing an array of accessory proteins from one or more protein families of interest,

- 25 (ii) contacting the array with compounds or peptides or proteins and with one or more membrane proteins or cytosolic fragments thereof of interest, either simultaneously or in sequence,
- (iii) determining whether said interaction is modulated by the presence of said compounds or peptides or proteins.

This method optionally comprises the additional step (iv) of quantitating the degree of modulation of the interaction.

5 The invention also provides the use of an array of accessory proteins as described herein to measure the relative catalytic activity of different members of a family of accessory proteins.

10 The invention also provides the use of an array of accessory proteins as described herein as an affinity surface on which to select antibodies from a library of phenotype-genotype-linked antibodies (e.g. phage displayed antibodies).

15 The invention also provides the use of an array of accessory proteins as described herein for determining the effect of post-translational modifications on the interactions of accessory proteins with membrane proteins and/or the properties of said membrane proteins or accessory proteins.

20 Subunit arrays according to the invention can comprise tagged protein constructs that are each expressed and immobilised in a functional manner in a spatially defined format. The tagged protein constructs can be drawn from groups of accessory protein subunits such as the cytoplasmic auxiliary β -subunits of voltage-gated K^+ or Ca^{2+} ion-channels, G-proteins, or globular accessory proteins that interact with bulk transporters. Binding of a labelled probe, which can be another channel subunit, associating protein, interaction
25 domain, peptide or other potential ligand can be investigated using technically simple protocols in a high throughput manner. Binding of complex mixtures or labelled or unlabelled proteins from recombinant systems or cell lysates can also be examined. An array of identical subunits is suited to screening large numbers of potential binding partners and obtaining detailed binding

information. Alternatively, an array of different proteins, representing subunits of different subtypes and species is most suited to examining the specificity of ligand binding.

5 Such arrays can be used to study ion channels, including the ligand-gated ion channel class of receptors, which exist as multi-subunit complexes, consisting of channel-forming subunits, modulatory proteins and proteins involved in subcellular location of the channel. Interactions between channel subunits may be mediated by defined intracellular domains. Voltage gated K^+ and Ca^{2+} channels co-assemble with structurally similar cytoplasmic β -subunits
10 via well-defined domains within the α -subunit [7,21,22]. These can affect channel gating to various extents and can dramatically alter surface expression efficiency of α -subunits through mechanisms that may resemble or mimic the interaction of membrane proteins with authentic molecular chaperones [2].

15 Another application of the arrays of the invention is in the study of receptors, for example, G-protein-coupled receptors (GPCRs). These constitute the largest family of cell surface molecules involved in signal transmission, with over 1000 heptahelical proteins identified in the human
20 genome. GPCRs transduce extracellular signals by activating a subset of trimeric G-proteins. Binding sites can be determined for specific GPCR-G-protein partners, such as rhodopsin and the retinal G-protein transducin [23]. However, the binding determinants of the GPCRs do not form discrete domains and it is difficult to predict the subset of G-proteins a receptor will bind to [24].
25 An array based method for determining such interactions with the large number of orphan GPCRs currently under investigation would be highly advantageous. The effects of GPCRs are modulated for example, by interactions and binding with G-protein-coupled receptor kinases (GRKs) and arrestins, which lead to receptor desensitisation and internalisation [25]. It has been demonstrated that

the interaction with arrestin is robust enough to be detected by coimmunoprecipitation [17] and can be inhibited by synthetic peptides [26]. As such, it is a potential target for investigation using an *in vitro* binding method.

5

A further application of the arrays of the invention is in the study of transmembrane transporter proteins. These proteins control the selective uptake of nutrients and export of metabolic products, regulate the balance of ions and solutes between the exterior and interior of the cell and modulate synaptic transmission by the removal of neurotransmitters from the synaptic cleft. A major regulatory mechanism for these proteins involves translocation to and from cell membranes. However, evidence is emerging that regulation by protein-protein interaction with transporters located in the cell membrane also occurs. e.g. Phosphorylation-dependent *in vitro* binding between the membrane bound *E. coli* transporter enzyme IICB^{Glc} and the global repressor Mlc has indicated a mechanism of transcriptional control [27]. Binding of a C-terminal domain of the glucose transporter GLUT-1 to a transmembrane regulatory protein, stomatin, has also been demonstrated by affinity column chromatography [28].

20

The term "array" as defined herein refers to a spatially defined arrangement of one or more protein moieties in a pattern on a surface. Preferably the protein moieties are attached to the surface either directly or indirectly. The attachment can be non-specific (e.g. by physical absorption onto the surface or by formation of a non-specific covalent interaction). In a preferred embodiment the protein moieties are attached to the surface through a common marker moiety linked to each protein, for example as described in WO 01/57198.

25

Thus, for example, each position in the pattern can contain one or more copies of:

30

- a) a sample of a single protein type (in the form of a monomer, dimer, trimer, tetramer or higher multimer);
- 5 b) a sample of a single protein type bound to an interacting molecule (e.g. DNA, antibody, other protein);
- c) a sample of a single protein type bound to a synthetic molecule (e.g. peptide, chemical compound); or
- 10 d) A heteromeric mixture of 2 or more proteins from a given accessory protein family.

15 The surface which supports the array can be coated/derivatised by chemical treatment, for instance. Examples of suitable surfaces include glass slides, polypropylene or polystyrene, silica, gold or metal support or membranes made of, for example, nitrocellulose, PVDF, nylon or phosphocellulose. The format of the array can be that of a microwell plate or a microarray.

20 The use of a protein array format according to the invention has many advantages. For example, an array of components of a membrane protein assembly, such as auxiliary subunits, associated proteins and channel subunit domains, permits interactions with binding partners in the solution phase to be examined. Binding parameters can be accurately determined and the effects of
25 modulators or inhibitors of binding can be studied in a highly parallel manner.

A number of recent publications [for example reference 8] have shown that arrays of functional proteins allow the individual members of an array to be screened simultaneously under identical conditions. This allows highly parallel

and rapid experiments compared with other techniques, leading to directly comparable results across many proteins. These qualities set protein arrays apart from other assays for protein function, such as Y2H and immunoprecipitations/pull-downs, where the cellular compartmentalisation that is implicit in these other methods effectively divides each protein collection into individual proteins and thus individual assays.

Protein arrays according to the invention can preserve the functional activity of proteins when they are specifically immobilised, allowing biological activity to be directly measured. In addition they provide a direct method for determining the effect of a potential inhibitor entities on on the interactions observed which is not possible in a comparable manner using immunoprecipitations and pull-down assays.

Protein arrays according to the invention can be used to quantitate binding constants (K_d) for observed interactions and also allow the concentration of a compound required to inhibit a given interaction to be measured through determination of IC_{50} values.

Results obtained from interrogation of arrays of the invention can be quantitative (e.g. measuring binding or catalytic constants K_D & K_M), semi-quantitative (e.g. normalising amount bound against protein quantity) or qualitative (e.g. functional vs. non-functional). By quantifying the signals for replicate arrays where the ligand is added at several (for example, two or more) concentrations; both the binding affinities and the active concentrations of protein in the spot can be determined. For example, quantitative results, K_D and B_{max} , which describe the affinity of the interaction between ligand and protein and the number of binding sites for that ligand respectively, can be derived from protein array data. Briefly, either quantified or relative amounts

of ligand bound to each individual protein spot can be measured at different concentrations of ligand in the assay solution. Assuming a linear relationship between the amount of protein and bound ligand, the (relative) amount of ligand bound to each spot over a range of ligand concentrations used in the assay can be fitted to equation 1, rearrangements or derivations.

$$\text{Bound ligand} = B_{\max} / ((K_D/[L]) + 1) \quad (\text{Equation 1})$$

[L] = concentration of ligand used in the assay

The inventors have produced a functional array of membrane protein accessory proteins to provide a tool for the rapid investigation of binding parameters and specificity of ligands. The ligands can be other proteins, such as binding domains of other membrane protein subunits, peptides or potential therapeutic compounds to modulate complex assembly. The methodology provides for the determination of accurate binding constants in a highly parallel format.

The invention will now be further described by way of the following example which refers to the following figures in which:

Figure 1 shows western blots of β subunit crude lysates. 10 μ l of crude lysate and cleared lysate from each of the β subunit expressing clones were ran using SDS PAGE. Gels were transferred and membranes were probed with streptavidin (A) and anti His antibody (B). Lanes were loaded: 1&2 Human β 1, 3&4 Human β 2, 5&6 Human β 3, 7&8 Rat β 1, 9&10 Rat β 2, 11&12 Rat β 3. Odd lanes –crude lysate, even lanes - cleared lysate.

Figure 2 shows SDS PAGE of purified Kv β subunits. Lanes 1&8 Mr markers, 2 Human β 1, 3 Human β 2, 4 Human β 3, 5 Rat β 1, 6 Rat β 2, 7 Rat β 3

Figure 3 shows UV-Visible absorbance spectra of purified Human and Rat Kv β subunits. Legend: Blue; Human β 1, pink; Human β 2, yellow; Human β 3, cyan; Rat β 1, purple; Rat β 2, brown; Rat β 3. Inset shows in more detail the peak at 360 nm.

5

Figure 4 shows a Kv β subunit co-precipitation assay. A; Kv β subunit lysates were added to Kv α subunit coated anti FLAG beads (lanes 7-12) and to uncoated anti FLAG beads (lanes 1-6). After incubation for 1h the beads were washed, and boiled in SDS sample buffer before running on SDS PAGE. The gel was transferred to nitrocellulose membrane and biotinylated Kv β subunits visualized by using a streptavidin HRP conjugate. B; the bands from the western blot were quantified and plotted.

10

Figure 5 shows immobilisation of Kv β subunits in streptavidin coated microtitre plates. Kv β subunit lysates (original concentration approximately 3.5 mg/ml) were serially diluted and added to wells of a streptavidin coated microtitre plate. After washing to remove unbound protein, Kv β subunits were quantified by using a Cy3 labelled anti His antibody. Bound antibody was quantified fluorometrically in a Packard fusion microtitre plate reader equipped with 550 and 570 nm excitation and emission filters respectively.

15

20

Figure 6 shows binding of Kv α subunit T1 domain to the Kv β subunit microtitre plate array. Diluted crude α subunit T1 domain lysate was added to each well of a Kv β subunit microtitre plate array. After incubation the wells were washed to remove unbound Kv α subunit T1 domain. Remaining bound Kv α subunit T1 domain was measured by using the FLAG tag and anti FLAG antibodies and visualized by using a HRP conjugate secondary antibody and colourmetric substrate.

25

Figure 7 shows binding curves for SPL2 peptide to Kv β subunit array. Peptide SPL2 was bound to the Kv β subunit array. After washing the amount remaining bound to the array was quantified fluorimetrically. The data has been fitted to binding curves. Blue triangles; Rat Kv β 1, Black squares; Rat Kv β 2, open pink squares; Rat Kv β 3, red stars; Human Kv β 1, green circles; Human Kv β 2, Open cyan circles; Human Kv β 3.

Figure 8 shows inhibition of peptide binding to Kv β subunit array by Kv α subunit T1 domain. SPL2 peptide at approximately K_d was added to wells of Kv β subunit array in the presence and absence of purified Kv α subunit T1 domain. After washing, bound SPL2 peptide was quantified fluorimetrically

Figure 9 shows an antibody detection of microarrayed Kv β subunits. All Kv β subunits could be detected by using Cy3 labelled anti His antibody.

15

Figure 10 shows Kv α subunit T1 domain bound to microarrayed Kv β subunits. A Kv β subunit microarray was incubated with Kv α subunit T1 domain lysate. After washing Kv α subunit T1 domain bound to the β subunits could be detected using an anti FLAG antibody and Cy3 labelled anti mouse IgG.

20

Example 1

Voltage gated potassium (K_v) channels are recognised as therapeutic targets in many disorders including those of the CNS, heart, lungs and bladder. They are therefore important therapeutic and commercial targets. They consist of a tetrameric assembly of α -subunits which have six transmembrane spanning domains and are coupled to an assembly of cytoplasmic regulatory β -subunits.

25

To date, molecular cloning has identified at least 23 different gene products encoding Kv channel α subunits. Further diversification resulting from alternative splicing has also been demonstrated for a number of α subunits. Four families of channel-forming Kv subunits, Kv1 to Kv4, are derived from the *Drosophila* potassium channels, *Shaker*, *Shab*, *Shaw* and *Shal*, respectively. Each of these channel types has multiple subfamily members. A further four families of Kv channels, Kv5, Kv6, Kv8 and Kv9, have been identified that do not form functional channels alone. They can, however, combine with the channel-forming subunits to form functional channels with altered biophysical properties. At least two of these families of auxiliary α subunits (Kv6 and Kv9) have multiple subfamily members.

In addition to the molecular diversity afforded by homomeric and heteromeric tetramerisation of Kv channel α subunits, cytoplasmic β subunits can bind to the channel complex and modulate channel kinetics or cell surface expression. Three families, Kv β 1 to Kv β 3, have been identified to date, with 3 splice variants observed from the Kv β 1 gene. The β -subunit complex binds to a region of the N-terminus of the α -subunit known as the T1 domain and the presence of the subunit increases cell-surface expression of the functional ion channel. An additional role for Kv β 1 subunits in modulating channel gating kinetics has also been established.

Kv β subunit array

Materials and Methods for construction of Kv β subunit array

Cloning of His and biotin tagged Kv β subunit cDNAs

The Rat and Human Kv β 1, β 2 and β 3 subunit core domains cDNA were ligated into an *E.coli* expression vector downstream of sequence coding for a poly Histidine-tag and the BCCP domain from the *E.coli* *AccB* gene. The ligation mix was transformed into chemically competent XL10-Gold cells

(Stratagene) according to the manufacturer's instructions. The Ky β subunit cDNA sequence was checked by sequencing and found to correspond to the expected protein sequence – see Appendix.

5 *Expression of Ky β subunits in E.coli*

Colonies of XL10-Gold cells containing Ky β subunit plasmids were inoculated into 5 ml of LB medium containing ampicillin in 20 ml tubes and grown overnight at 37°C in a shaking incubator. 2 ml of overnight culture was used to inoculate another 200 ml of LB/ampicillin in 500 ml flasks and grown at 37°C
10 until an OD600 of ~1.0 was reached. IPTG and biotin was then added to final concentrations of 1mM and 50 μ M respectively and induction continued at 23°C for 4 hours. Cells were then harvested by centrifugation, cell pellets were washed in PBS x 3 and stored in aliquots at –80°C.

15 *Lysis of E.coli containing Ky β subunits*

Cell pellets were thawed on ice and 400 μ l of lysis buffer (PBS containing 0.1% Tween 20, 1 mg/ml lysozyme and 1 μ g/ml DNase I) was added and the cells were resuspended by pipetting. Lysis was aided by incubation on a rocker at room temperature for 30min before cell debris was collected by
20 centrifugation at 13000rpm for 10min at 4°C. The cleared supernatant of soluble protein was removed and used immediately.

Purification of Ky β subunits

Ky β subunits were purified by use of the hexahistidine tag. Cleared lysates
25 diluted in PBS containing 50 mM imidazole were added to a column containing Talon Cobalt affinity resin (Clontech). The column was washed with 10 column volumes of buffer and protein was eluted in 2 column volumes of PBS containing 300 mM imidazole.

SDS PAGE

Protein samples were boiled in SDS containing buffer for 5min prior to loading on 4-20% Tris-Glycine gels (NOVEX) and run at 200V for 45min. Gels were then used for Western blotting or protein was stained directly with Coomassie brilliant blue dye.

Western blotting

Protein was transferred onto PVDF membrane (Hybond-P, Amersham) and probed for the presence of various epitopes using standard techniques. For detection of the histidine-tag, membranes were blocked in 5% Marvel/PBST and anti-RGSHis antibody (QIAGEN) was used as the primary antibody at 1/1000 dilution. For detection of the biotin tag, membranes were blocked in Superblock/TBS (Pierce) and probed with Streptavidin/HRP conjugate (Amersham) at 1/2000 dilution in Superblock/TBS/0.1% Tween20. The secondary antibody for the RGSHis antibody was anti-mouse IgG (Fc specific) HRP conjugate (Sigma) used at 1/2000 dilution in Marvel/PBST. After extensive washing, bound HRP conjugates were detected using either ECLPlus (Amersham) and Hyperfilm ECL (Amersham) or by DAB staining (Pierce).

Spectra

UV-Vis Spectra (250–500 nm) of purified Ky β subunits were recorded using a Thermo spectronic scanning spectrophotometer. Proteins were diluted in elution buffer and elution buffer alone was used to take the baseline which is subtracted from all samples.

α subunit T1 domain interaction assay

The cDNA for the α subunit T1 domain (amino acids 33 - 135) was cloned downstream of sequences coding for a His-tag and a FLAG-tag in an *E.coli*

expression vector. Plasmids were checked by sequencing for correct sequence and induction of *E.coli* cultures showed expression of a His and FLAG tagged soluble protein of the expected size. To test for interaction between α subunit T1 domain and Ky β subunits, binding reactions were assembled containing
5 10 μ l Ky β subunit cleared lysates, 10 μ l anti-FLAG agarose in the presence and absence of 10 μ l α subunit T1 domain cleared lysate, in 500 μ l phosphate buffered saline containing 300mM NaCl, 0.1% Tween20 and 1% (w/v) bovine serum albumin. Reactions were incubated on a rocker at room temperature for 1 hour and FLAG bound complexes harvested by centrifugation at 5000rpm for
10 2min. After extensive washing in PBST, FLAG bound complexes were denatured in SDS sample buffer and Western blotted. Presence of biotinylated Ky β subunits were detected by Streptavidin/HRP conjugate.

Ky β subunit microtitre plate array fabrication

15 To 96 well streptavidin coated microtitre plates 100 μ l of optimised concentrations of Ky β subunit cleared lysates (typically 1 in 16 dilutions in PBS-Tween) were added to each well. Plates were incubated at room temperature with shaking for 45 mins before washing each well 3 times with 300 μ l of PBS-Tween. After which the plates were used in assays or stored at –
20 20°C in the presence of 50% (v/v) glycerol in PBS-Tween.

Ky β subunit array peptide binding assay

Ky β subunit interacting peptide (SPL2) based on a portion of the α subunit domain was designed, synthesized and fluorescein labeled. SPL2 peptide
25 appropriately diluted in PBS-Tween containing 0.1% w/v BSA was added at 100 μ l/well to the Ky β subunit coated microtitre plate. The peptide was incubated for 1 h at roomtemperature with shaking before unbound peptide was removed by washing 3 times in 300 μ l of PBS-Tween. 100 μ l of 6M Guanidine

HCl was added to each well before evaluation of Fluorescein labelled SPL2 peptide concentration in each well. The fluorescence of each well of a 96 well microtitre plates were read in a Packard fusion microtitre plate reader equipped with 485 and 520 nm excitation and emission filters respectively.

5

Kv β subunit array Kv α subunit T1 domain interaction assay

Kv α subunit T1 domain cleared lysate was diluted 1 in 10 in PBS-Tween containing 0.1% w/v BSA was added at 100 μ l/well to the Kv β subunit coated microtitre plate. The peptide was incubated for 1 h at room temperature with shaking before unbound α subunit T1 domain was removed by washing 3
10 timed in 300 μ l of PBS-Tween. Bound α subunit T1 domain was estimated by using appropriately diluted mouse anti FLAG antibody and anti mouse IgG secondary antibody HRP conjugate using standard ELISA procedures. HRP
15 was detected by addition of colourmetric HRP substrate 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and microtitre plates were read in a Packard fusion microtitre plate reader equipped with a 405 nm absorbance filter.

Kv β subunit microarray fabrication

20 Cleared lysates of Kv β subunit were loaded into a 384 well plate and printed onto glass microscope slides with a neutravidin immobilized on dextran coating (Xantec) using a Qarray microarraying robot (Genetix, UK) with a 4 pin microarraying head. Each lysate was spotted 16 times onto each array. After printing, arrays were incubated in a humid chamber at 4°C for 1 h before
25 washing in PBS-Tween. After washing arrays were ready for assay.

Antibody Detection of microarrayed Kv β subunits

Cy3 labelled anti His antibody was diluted to 1 μ g/ml in PBS-Tween + 0.1% (w/v) BSA and approximately 500 μ l was pipetted onto the slide. The slide was

incubated at room temperature with very slight shaking for 1 h before washing 2 x 2 mins in a large volume of PBS-Tween. Slides were centrifuged briefly at 2000g to remove liquid before scanning in a microarray scanner (Affymetrix 428 array scanner) equipped with excitation laser and emission filters appropriate for Cy3 fluorophore detection.

Kv α subunit T1 domain Binding to microarrayed Kv β subunits

Kv α subunit T1 domain cleared lysate was diluted 1 in 50 in PBS-Tween containing 1% w/v BSA and approximately 500 μ l was pipetted onto the slide.

The slide was incubated at room temperature with very slight shaking for 1 h before washing 2 x 2 mins in a large volume of PBS-Tween. Appropriately diluted Anti FLAG Antibody was then pipetted onto the array and incubated and washed as above before addition of Cy3 labelled anti mouse IgG. The slides were incubated and washed as above before centrifuging briefly at 2000g to remove liquid before scanning in a microarray scanner (Affymetrix 428 array scanner) equipped with excitation laser and emission filters appropriate for Cy3 fluorophore detection.

Results

Expression of Kv β subunits in E.coli

The Kv β subunit core domains were cloned downstream of the tac promoter in vector pQE80 into which the BCCP domain from the *E.coli* gene ACCB had already been cloned. The resultant protein would then be His and biotin tagged at its N-terminus. Figure 1 shows Western blot analysis of total and soluble protein from induced *E.coli* cultures. For all β subunits there are clear bands for His-tagged and biotinylated protein with a molecular weight of approximately 50 kDa. Bands of the same size are detected by a polyclonal antibody raised to

human Kv β 2 (Biosource) which cross-reacted with all the β subunits used (Data not shown).

Although His and biotin tags have been used in this array, other affinity tags (e.g. FLAG, myc, VSV) could be used to enable purification, detection and immobilization of the cloned proteins. Also an expression host other than *E. coli* may be used (e.g. yeast, insect cells, mammalian cells) if required.

Purification of Kv β subunits

Proteins can be purified before arraying by using an affinity tag. Here we have made use of the his tag by purifying the protein on Talon resin. Figure 2 shows that Kv β subunits purified in this way show only bands on SDS-PAGE that correspond to the Kv β subunit, or proteolysis products.

UV-Vis Absorbance Spectra

UV-Vis spectra were acquired for all Human and Rat Kv β subunits. Figure 3 shows that both Human and Rat Kv β 2 subunits contain a NAD(P)H cofactor as evidenced by their absorbance peaks at 360 nm.

α subunit T1 domain interaction assay

To confirm that the expressed Kv β subunits have retained native function an assay was devised where the Kv β subunits would be precipitated by binding to α subunit T1 domain coated beads. To anti FLAG beads FLAG tagged Kv α subunit T1 domain lysates were added. These were then mixed with lysates containing the Kv β subunits. Figure 4 shows that although the non-specific binding of Kv β subunits to anti FLAG beads was high, binding in the presence of the Kv α subunit T1 domain was increased. Also it can be seen that Rat Kv β 3 subunit has bound to Kv α subunit T1 domain coated beads in greater amounts than any other Kv β subunit.

Kv β subunit microtitre plate array fabrication

To confirm that streptavidin coated microtitre plates can be coated with Kv β subunits, lysates were serially diluted and added to wells of plates. Figure 5 shows that similar levels of specifically immobilized protein per well can be achieved.

Kv β subunit array α subunit T1 domain interaction assay

Figure 6 demonstrates specific binding of Kv α subunit T1 domain to all Kv β subunits. It can also be noted that Rat Kv β 3 subunit has bound more Kv α subunit T1 domain by far, mirroring the results of the co-precipitation assay.

Kv β subunit array peptide binding assay

SPL2 peptide was added to a Kv β subunit microtitre plate array at a range of concentrations from 100 to 1600 μ M. After incubation for 1h the wells were washed to remove unbound peptide. The remaining peptide was quantified fluorometrically. The results (shown in Fig 7) provide fits to the data allowing estimations of K_d and B_{max} for each of the Kv β subunits (Table 1).

Beta Subunit	Kd (μ M)
R1	189.6
R2	196.6
R3	54.6
H1	225.8
H2	184.1
H3	116.4

Table 1. Estimates of K_d and B_{max} for each of the Kv β subunits. The data in Figure 7 were fitted to binding curves using curve-fitting software.

Inhibition of peptide binding to Kv β subunit array by Kv α subunit T1 domain

Binding of SPL2 peptide to $Kv\beta$ subunit array was inhibited in the presence of $Kv \alpha$ subunit T1 domain. In Figure 8 it can be seen that for Rat $Kv\beta 1$ and 2 subunits peptide binding is reduced.

5 *Antibody Detection of microarrayed $Kv\beta$ subunits*

Microarrayed $Kv\beta$ subunits are shown to be specifically immobilised on streptavidin coated glass microscope slides. In Figure 9 it can be seen that the inclusion of free biotin in the spotting solution completely inhibited the immobilisation of $Kv \beta 3$. All $Kv \beta$ subunits are present on the array also the
10 immobilisation BCCP tag is present on the array.

$Kv \alpha$ subunit T1 domain Binding to microarrayed $Kv\beta$ subunits

$Kv \beta$ subunits immobilised on an array are still capable of binding $Kv \alpha$ subunit T1 domain. Figure 10. shows that $Kv \alpha$ subunit T1 domain can be
15 detected after binding to immobilised $Kv \beta$ subunits. It can also be seen from Figure 10 that the immobilised affinity tag has little binding of the $Kv \alpha$ subunit T1 domain.

20

25

30

References

1. Jan LY and Jan YN (1997) Receptor-regulated ion channels. *Curr Opin Cell Biol* 9(2):155-60
5
2. Trimmer, J.S. (1998) Regulation of ion channel expression by cytoplasmic subunits. *Curr. Opin. Neurobiol.* 8, 370-374.
- 10 3. Perez-Garcia, MT *et al.*, (1995) Functional properties of cardiac L-type calcium channels transiently expressed in HEK293 cells. Roles of alpha 1 and beta subunits. *J. Gen. Physiol.* 105, 289-305.
- 15 4. Brady AE, Limbird LE. (2002) G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction . *Cell Signal* 14(4):297-309
- 20 5. Ruiz-Velasco V, Ikeda SR, Puhl HL. (2002) Cloning, tissue distribution, and functional expression of the human G protein {beta}4-subunit. *Physiol Genomics* 8(1):41-50
6. Walker, D *et al.* (1998) A β_4 isoform-specific interaction site in the carboxyl-terminal region of the voltage-dependent Ca^{2+} channel α_{1A} subunit. *J. Biol. Chem.*, 273, 2361-2367.
- 25 7. Xu and Li, (1998) Auxiliary Subunits of Shaker-type potassium channels. *Trends. Cardiovasc. Med.*, 8, 229-234.

8. Zhu H, Klemic JF, Chang S, Bertone P, Casamayor A, Klemic KG, Smith D, Gerstein M, Reed MA, Snyder M. Analysis of yeast protein kinases using protein chips. *Nat Genet* (2000) 26(3):283-9
- 5 9. Dolly, JO and Parcej, DN (1996) Molecular properties of voltage-gated K⁺ channels. *J. Bioenerg. Biomembr.*, 28, 231-253.
- 10 10. Scott, VE *et al.*, (1990) Alpha-dendrotoxin acceptor from bovine brain is a K⁺ channel protein. Evidence from the N-terminal sequence of its larger subunit. *J. Biol. Chem.*, 265, 20094-20097.
11. Wang, Z *et al.*, (1996) Comparison of Binding and Block Produced by Alternatively Spliced Kv β 1 Subunits. *J. Biol. Chem.*, 271, 28311-28317.
- 15 12. Restituito, S *et al.*, (2001) Ca²⁺ Channel Inactivation Heterogeneity Reveals Physiological Unbinding of Auxiliary Subunits. *Biophys. J.* 81, 89-96.
13. Strader, CD *et al.* (1994) Structure and function of G-protein-coupled receptors. *Annu. Rev. Biochem.*, 63, 101-132.
- 20 14. Strader, CD *et al.* (1995) The family of G-protein-coupled receptors. *FASEB J.*, 9, 745-754.
- 25 15. Tucker, S.J. and Ashcroft, F.M. (1999) Mapping of the physical interaction between the intracellular domains of an inwardly rectifying potassium channel, Kir6.2. *J. Biol. Chem.*, 274, 33393-33397.

16. Yokoyama, CT *et al.* (1997) Phosphorylation of the synaptic protein interaction site on N-type calcium channels inhibits interactions with SNARE proteins. *J. Neurosci.*, **17**, 6929-6938.
- 5 17. Gelber, E *et al.*, (1999) Structure and function of the third intracellular loop of the 5-HT_{2A} receptor: The third intracellular loop is α -helical and binds purified arrestins.
- 10 18. Weixel, KM and Bradbury, NA (2001) μ 2 Binding directs the cystic fibrosis transmembrane conductance regulator to the clathrin-mediated endocytic pathway. *J. Biol. Chem.*, **49**, 46251-46259.
- 15 19. Tu, JC *et al.* (1998) Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. *Neuron*, **21**, 717-726.
- 20 20. Shieh, B-H and Zhu, M-Y (1996) Regulation of the TRP Ca⁺ channel by INAD in *Drosophila* photoreceptors. *Neuron*, **16**, 991-998.
- 20 21. Pongs, O., Leicher, T., Berger, M. *et al.* (1999) Functional and molecular aspects of voltage-gated K⁺ channel β subunits.
- 25 22. Walker, D. and Waard, M. (1998) Subunit interaction sites in voltage-dependent Ca²⁺ channels: role in channel function.
- 25 23. Onrust, R, Herzmark, P *et al.* (1997) Receptor and $\beta\gamma$ binding sites in the α subunit of the retinal G-protein transducin. *Science*, **275**, 381-384
24. Bourne, HR (1997) How receptors talk to trimeric G proteins. *Curr. Opin. Cell. Biol.*, **9**, 134-142.

25. Ferguson, SSG (2001) Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling. *Pharmacol. Rev.*, 53, 1-24.

5

26. Krupnick, JG *et al.*, (1994) Arrestin-rhodopsin interaction. Multi-site binding delineated by peptide inhibition. *J. Biol. Chem.* 269, 3226-3232.

10

27. Nam, T-W *et al.*, (2001) The *Escherichia coli* glucose transporter enzyme IICB^{Glc} recruits the global repressor Mlc. *EMBO J.*, 20, 491-498.

28. Zhang, J-Z *et al.*, (2001) Overexpression of stomatin depresses GLUT-1 glucose transporter activity. *Am. J. Physiol. Cell. Physiol.*, 280, C1277-C1283.

Appendix 1

Protein Sequence Human Kv β 1 subunit core domain (residues 87 – 419):

5 GTGMKYRNLGKSGLRVSCGLGLGTWVTFGGQISDEVAERLMTIAYESG
 VNLFDTAEVYAAGKAEVILGSIKKKGWRRSSLVITTKLYWGGKAETE
 RGLSRKHIIIEGLKGSLQRLQLEYVDVVFANRPDSNTPMEEIVRAMTHVI
 NQGMAMYWGTSRWSAMEIMEAYSVARQFNMIPPVCEQAEYHLFQRE
 KVEVQLPELYHKIGVGAMTWSPLACGIISGKYGNGVPRESSRSLKCYQ
 10 WLKERIVSEGRKQQNKLDLSPIAERLGCTLPQLAVAWCLRNEGVS
 VLLGSSTPEQLIENLGAIQVLPKMTSHVVNEIDNILRNKPYSKKDYRS

Protein Sequence Human Kv β 2 subunit core domain (residues 36 – 364):

15 GLQFYRNLGKSGLRVSCGLGLGTWVTFGGQITDEMAEQLMTLAYDNGI
 NLFDTAEVYAAGKAEVVLGNIKKKGWRRSSLVITTKIFWGGKAETER
 GLSRKHIIIEGLKASLERLQLEYVDVVFANRPDPNTPMEETVRAMTHVIN
 QGMAMYWGTSRWSSMEIMEAYSVARQFNLTTPICEQAEYHMFQREK
 VEVQLPELFHKIGVGAMTWSPLACGIVSGKYDSGIPPYSRSLKGYQW
 LKDKILSEGRRQQAKLKEQAIAERLGCTLPQLAIAWCLRNEGVS
 20 LGASNADQLMENIGAIQVLPKLSSSIHEIDSILGNKPYSKKDYRS

Protein Sequence Human Kv β 3 subunit core domain (residues 75 – 404):

GTGMKYRNLGKSGLRVSCGLGLGTWVTFGSQISDETAEDVLTVAYEHG
 VNLFDTAEVYAAGKAERTLGNIKSKGWRRSSYVITTKIFWGGQAETE
 RGLSRKHIIIEGLRGSLERLQLGYVDIVFANRSDPNCPMEEIVRAMTYVI
 25 NQGLALYWGTSRWGA AEIMEAYSMARQFNLI PPVCEQAEHHLFQREK
 VEMQLPELYHKIGVGSVTWYPLACGLITSKYDGRVPDTCRASIKGYQW
 LKDKVQSEDGKKQQA KVM DLLPVAHQLGCTVAQLAIAWCLRSEGVSS
 VLLGVSSAEQLIEHLGALQVLSQLTPQTVM EIDG LLGNKPHSKK

Protein Sequence Rat Kv β 1 subunit core domain:

30 GTGMKYRNLGKSGLRVSCGLGLGTWVTFGGQISDEVAERLMTIAYESG
 VNLFDTAEVYAAGKAEVILGSIKKKGWRRSSLVITTKLYWGGKAETE
 RGLSRKHIIIEGLKGSLQRLQLEYVDVVFANRPDSNTPMEEIVRAMTHVI
 NQGMAMYWGTSRWSAMEIMEAYSVARQFNMIPPVCEQAEYHLFQRE
 35 KVEVQLPELYHKIGVGAMTWSPLACGIISGKYGNGVPRESSRSLKCYQ
 WLKERIVSEGRKQQNKLDLSPIAERLGCTLPQLAVAWCLRNEGVS
 VLLGSSTPEQLIENLGAIQVLPKMTSHVVNEIDNILRNKPYSKKDYRS

Protein Sequence Rat Kv β 2 subunit core domain:

40 GLQFYRNLGKSGLRVSCGLGLGTWVTFGGQITDEMAEHLMTLAYDNGI
 NLFDTAEVYAAGKAEVVLGNIKKKGWRRSSLVITTKIFWGGKAETER
 GLSRKHIIIEGLKASLERLQLEYVDVVFANRPDPNTPMEETVRAMTHVIN
 QGMAMYWGTSRWSSMEIMEAYSVARQFNLI PPICEQAEYHMFQREKV

EVQLPELFHKIGVGAMTWSPLACGIVSGKYDSGIPPYSRASLKG YQWL
KDKILSEEGRRQQAKLKE LQAIAERLGCTLPQLAIAWCLRNEGVS SVLL
GASNAEQLMENIGAIQVLPKLSSSIVHEIDSILGNKPYSKKDYRS

5 *Protein Sequence Rat Kv β 3 subunit core domain (residues 75 – 404):*

GTGMKYRNLGKSGLRV SCLGLGTWVTFGSQISDETAEDLLTVAYEHG
VNLFDTAEVYAAGKAERT LGNILKSKGWRRSSYVITTKIFWGGQAETE
RGLSRKHIIIEGLQGSLDRLQLEYVDIVFANRSDPSSPMEEIVRAMTYVIN
QGLALYWGTSRWSAAEIMEA YSMARQFNLI PPVCEQAENHFFQREKV
10 EMQLPELYHKIGVGSVTWSPLACSLITSKYDGQVPDACKATVKGYQW
LKEKVQSEDGKKQARVTDLLPIAHQLGCTVAQLAIAWCLRSEGVSSV
LLGVSSAEQLMEHLGSLQVLGQLTPQTVMEIDALLGNKSHSKK

15

20

25

CLAIMS:

1. An array of cytosolic accessory proteins which in their natural state are normally bound to membrane proteins.
5
2. The array of claim 1, wherein said membrane proteins are members of a family of homologous membrane proteins
3. The array of claim 2, wherein said homologous membrane proteins are selected from the group consisting of ion-channels, G protein coupled receptors and transmembrane transporters.
10
4. The array of claim 1, wherein said accessory proteins are members of a family of homologous accessory proteins.
15
5. The array of claim 4, wherein said family is selected from the group consisting of ion-channel subunits, receptor interacting proteins and accessory proteins to membrane transporter proteins.
6. The array of claim 4 wherein said family is selected from the group consisting of K⁺-channel β -subunits, Ca²⁺-channel β -subunits, G protein subtypes and accessory proteins for transporters
20
7. The array of claim 4, wherein said family is selected from the group of consisting of Kv β -subunits channel, Calcium channel β -subunits, G_s family, G_t family, G_i family, G_{i-0} family, G_{q-11} family, G α -sensory family, $\beta\gamma$ family and accessory proteins to transporters.
25

8. A method for determining the interacting accessory proteins for a given membrane protein, said method comprising the steps of:

- (i) providing an array of candidate accessory proteins from one or more protein families of interest,
- 5 (ii) contacting the array with cytosolic fragments of said membrane protein and/or cytosolic fragments of other related membrane protein family members,
- (iii) detecting/identifying the interacting partners.

10 9. A method for screening compounds or peptides or proteins for the ability to interact selectively with an accessory protein, said method comprising the steps of:

- (i) providing an array of accessory proteins from one or more protein families of interest,
- (ii) contacting the array with compounds or peptides or proteins,
- 15 (iii) identifying the interacting partners.

10. The method of claim 9, which method comprises the additional step (iv) of quantitating the interaction of the interacting partners.

20 11. A method for screening compounds or peptides or proteins for the ability to selectively modulate the interaction between an accessory protein and a membrane protein, said method comprising the steps of

- (i) providing an array of accessory proteins from one or more protein families of interest,
- 25 (ii) contacting the array with compounds or peptides or proteins and with one or more membrane proteins or cytosolic fragments thereof of interest, either simultaneously or in sequence,
- (iii) determining whether said interaction is modulated by the presence of said compounds or peptides or proteins.

12. The method of claim 11, said method comprising the additional step (iv) of quantitating the degree of modulation of the interaction.

5 13. The use of an array of accessory proteins as described herein to measure the relative catalytic activity of different members of a family of accessory proteins.

10 14. The use of an array of accessory proteins as described herein as an affinity surface on which to select antibodies from a library of phenotype-genotype-linked antibodies (e.g. phage displayed antibodies).

15 15. The use of an array of accessory proteins as described herein for determining the effect of post-translational modifications on the interactions of accessory proteins with membrane proteins and/or on the properties of said membrane proteins.or accessory

20




Figure 1




Figure 2









Figure 3

**Figure 4****Figure 5**

**Figure 6****Figure 7****Figure 8**




Figure 9




Figure 10

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.